137 related articles for article (PubMed ID: 15528058)
1. Misclassifying the indications for prostate-specific antigen testing may bias case-control studies of the efficacy of prostate cancer screening.
Hoffman RM; Adams-Cameron ML; Murata GH
J Clin Epidemiol; 2004 Oct; 57(10):1071-5. PubMed ID: 15528058
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
Agalliu I; Weiss NS; Lin DW; Stanford JL
Cancer Causes Control; 2007 Nov; 18(9):931-7. PubMed ID: 17641982
[TBL] [Abstract][Full Text] [Related]
3. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
Godley PA; Carpenter WR
J Clin Epidemiol; 2007 Feb; 60(2):176-80. PubMed ID: 17208124
[TBL] [Abstract][Full Text] [Related]
4. Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study.
Kopec JA; Goel V; Bunting PS; Neuman J; Sayre EC; Warde P; Levers P; Fleshner N
J Urol; 2005 Aug; 174(2):495-9; discussion 499. PubMed ID: 16006879
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of prostate cancer in aging males receiving PSA (prostate specific antigen) screening test (A campaign for celebration of Siriraj Established Day).
Srinualnad S; Charoenkraikamol C; Toraksa S; Uiprasertkul M; Amornvesukit T; Taweemonkongsap T; Udompunturak S; Nualyong C; Tantiwong A
J Med Assoc Thai; 2006 Jan; 89(1):37-42. PubMed ID: 16583579
[TBL] [Abstract][Full Text] [Related]
6. The effectiveness of screening for prostate cancer: a nested case-control study.
Concato J; Wells CK; Horwitz RI; Penson D; Fincke G; Berlowitz DR; Froehlich G; Blake D; Vickers MA; Gehr GA; Raheb NH; Sullivan G; Peduzzi P
Arch Intern Med; 2006 Jan; 166(1):38-43. PubMed ID: 16401808
[TBL] [Abstract][Full Text] [Related]
7. Population-based study of prostate-specific antigen testing and prostate cancer detection in clinical practice in northern Sweden.
Pilebro B; Johansson R; Damber L; Damber JE; Stattin P
Scand J Urol Nephrol; 2003; 37(3):210-2. PubMed ID: 12775278
[TBL] [Abstract][Full Text] [Related]
8. Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.
Sayre EC; Bunting PS; Kopec JA
Can J Urol; 2009 Feb; 16(1):4463-71. PubMed ID: 19222884
[TBL] [Abstract][Full Text] [Related]
9. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen testing in general practice: a survey among 325 general practitioners in Denmark.
Jønler M; Eddy B; Poulsen J
Scand J Urol Nephrol; 2005; 39(3):214-8. PubMed ID: 16118092
[TBL] [Abstract][Full Text] [Related]
11. Measuring the psychosocial impact of population-based prostate-specific antigen testing for prostate cancer in the UK.
Brindle LA; Oliver SE; Dedman D; Donovan JL; Neal DE; Hamdy FC; Lane JA; Peters TJ
BJU Int; 2006 Oct; 98(4):777-82. PubMed ID: 16978272
[TBL] [Abstract][Full Text] [Related]
12. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
13. The impact of informed consent on patient interest in prostate-specific antigen screening.
Wolf AM; Nasser JF; Wolf AM; Schorling JB
Arch Intern Med; 1996 Jun; 156(12):1333-6. PubMed ID: 8651843
[TBL] [Abstract][Full Text] [Related]
14. Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.
Andriole GL; Levin DL; Crawford ED; Gelmann EP; Pinsky PF; Chia D; Kramer BS; Reding D; Church TR; Grubb RL; Izmirlian G; Ragard LR; Clapp JD; Prorok PC; Gohagan JK;
J Natl Cancer Inst; 2005 Mar; 97(6):433-8. PubMed ID: 15770007
[TBL] [Abstract][Full Text] [Related]
15. Prostate cancer screening decisions: results from the National Survey of Medical Decisions (DECISIONS study).
Hoffman RM; Couper MP; Zikmund-Fisher BJ; Levin CA; McNaughton-Collins M; Helitzer DL; VanHoewyk J; Barry MJ
Arch Intern Med; 2009 Sep; 169(17):1611-8. PubMed ID: 19786681
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer association studies: pitfalls and solutions to cancer misclassification in the PSA era.
Platz EA; De Marzo AM; Giovannucci E
J Cell Biochem; 2004 Feb; 91(3):553-71. PubMed ID: 14755685
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer and prostate-specific antigen (PSA) screening in Austria.
Vutuc C; Schernhammer ES; Haidinger G; Waldhör T
Wien Klin Wochenschr; 2005 Jul; 117(13-14):457-61. PubMed ID: 16091872
[TBL] [Abstract][Full Text] [Related]
18. Prostate-specific antigen assay using whole blood samples spotted on filter paper and its application to mass screening for prostate cancer.
Nanri M; Nanri K; Fujiyama C; Tokuda Y; Nakamura K; Uozumi J
Int J Urol; 2007 Jun; 14(6):505-9. PubMed ID: 17593094
[TBL] [Abstract][Full Text] [Related]
19. Digital rectal examination is barrier to population-based prostate cancer screening.
Nagler HM; Gerber EW; Homel P; Wagner JR; Norton J; Lebovitch S; Phillips JL
Urology; 2005 Jun; 65(6):1137-40. PubMed ID: 15922431
[TBL] [Abstract][Full Text] [Related]
20. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
